Twisting arms to angiotensin receptor blockers/antagonists: The turn of cancer

European Heart Journal

Volumn 32, Issue 1, 2011, Pages 19-22

  Volpe, Massimo ^a,b   Azizi, Michel ^c,d,e   Danser, A H Jan ^f   Nguyen, Genevieve ^e   Ruilope, Luis M ^g  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e INSERM   (France)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; CAPTOPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LOSARTAN; PLACEBO; RAMIPRIL; RECOMBINANT ANTIBODY; RESERPINE; TELMISARTAN; VALSARTAN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CONGESTIVE HEART FAILURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY CANCER; LOW DRUG DOSE; LUNG ADENOCARCINOMA; MELANOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOVASCULAR DISEASES; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 78651273011     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq382     Document Type: Article

References (43)

1. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007;20:72-80.
2. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, Cesana G, Mancia G. Discontinuation of and changes in drug therapy for hypertension among newly treated patients: a population-based study in Italy. J Hypertens 2008;26:819-824.
3. Zanchetti A, Mancia G, Black HR, Oparil S, Waeber B, SchmieDer RE, Bakris GL, Messerli FH, Kjeldsen SE, Ruilope LM. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009;27:673-679.
4. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 2008;26:1477-1486.
5. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan vs. captopril in patients over 65 with heart failure (Evaluation of Losartan in the ElDerly Study, ELITE). Lancet 1997;349:747-752.
6. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000 May 6;355:1582-1587.
7. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-760.
8. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
9. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
10. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003;362:759-766.
11. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004;329:1248-1249.
12. Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. J Hypertens 2009;27:941-946.
13. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005;26: 2381-2386.
14. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, AnDerson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358: 1547-1559.
15. Verma S, Mamdani MM, Al-Omran M, Melo M, Rouleau JL. Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elDerly patients: a population-based color study (UMPIRE study results). J Am Soc Hypertens 2007;1:286-294.
16. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.
17. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010;11:627-636.
18. Nissen SE. Angiotensin-receptor blockers and cancer: urgent regulatory review needed. Lancet Oncol 2010;11:605-606.
19. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med 2002;112:479-486.
20. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001;22:1343-1352.
21. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352:179-184.
22. Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens 2009;23:623-635.
23. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008;29:1675-1684.
24. Arrieta O, Pineda-Olvera B, Guevara-Salazar P, Hernandez-Pedro N, Morales-Espinosa D, Ceron-Lizarraga TL, Gonzalez-De la Rosa CH, Rembao D, Segura-Pacheco B, Sotelo J. Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. Br J Cancer 2008;99:160-166.
25. Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest 2002;82:747-756.
26. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996;98:671-679.
27. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladDer cancer. Clin Cancer Res 2006;12:2888-2893.
28. Redondo-Müller MA, SteVanovic-Walker M, Barker S, Puddefoot JR, Vinson GP. Anti-cancer actions of a recombinant antibody (R6313/G2) against the angioten-sin II AT1 receptor. Endocr Relat Cancer 2008;15:277-288.
29. Doi C, Egashira N, Kawabata A, Maurya DK, Ohta N, Uppalapati D, Ayuzawa R, Pickel L, Isayama Y, Troyer D, Takekoshi S, Tamura M. Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer 2010;10:67.
30. Pickel L, Matsuzuka T, Doi C, Ayuzawa R, Maurya DK, Xie SX, Berkland C, Tamura M. Overexpression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biol Ther 2010;9:277-285.
31. Benndorf R, Böger RH, Ergün S, Steenpass A, Wieland T. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res 2003;93:438-447.
32. Kanehira T, Tani T, Takagi T, Nakano Y, Howard EF, Tamura M. Angiotensin II type 2 receptor gene deficiency attenuates susceptibility to tobacco-specific nitrosamine-induced lung tumorigenesis: involvement of transforming growth factor-beta-dependent cell growth attenuation. Cancer Res 2005;65:7660-7665.
33. Moltzer E, Verkuil AV, Van Veghel R, Danser AH, Van Esch JH. Effects of angioten-sin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation. Hypertension 2010;55:516-522.
34. Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA, Gallagher PE. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res 2007;67:2809-2815.
35. Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 2009;8:1676-1683.
36. Gallagher PE, Tallant EA. Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 2004;25:2045-2052.
37. Azizi M, Junot C, Ezan E, Menard J. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline. Clin Exp Pharmacol Physiol 2001;28:1066-1069.
38. Azizi M, Ezan E, Reny JL, Wdzieczak-Bakala J, Gerineau V, Menard J. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. Hypertension 1999;33: 879-886.
39. Wang D, Carretero OA, Yang XY, Rhaleb NE, Liu YH, Liao TD, Yang XP. N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. Am J Physiol Heart Circ Physiol 2004;287:H2099-H2105.
40. Liu JM, Lawrence F, Kovacevic M, Bignon J, Papadimitriou E, Lallemand JY, Katsoris P, Potier P, Fromes Y, Wdzieczak-Bakala J. The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood 2003;101:3014-3020.
41. Waeckel L, Bignon J, Liu JM, Markovits D, Ebrahimian TG, Vilar J, Mees B, Blanc-Brude O, Barateau V, Le Ricousse-Roussanne S, Duriez M, Tobelem G, Wdzieczak-Bakala J, Levy BI, Silvestre JS. Tetrapeptide AcSDKP induces postis-chemic neovascularization through monocyte chemoattractant protein-1 signaling. Arterioscler Thromb Vasc Biol 2006;26:773-779.
42. Liu JM, Kusinski M, Ilic V, Bignon J, Hajem N, Komorowski J, Kuzdak K, Stepien H, Wdzieczak-Bakala J. Overexpression of the angiogenic tetrapeptide AcSDKP in human malignant tumors. Anticancer Res 2008;28:2813-2817.
43. Cruciat CM, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D, Boutros M, Niehrs C. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science 2010; 327:459-463.